Aerolase is marking its 30-year anniversary in 2026, reflecting on three decades of laser technology development and its ongoing role in dermatology and aesthetic practice.
Founded in 1996, the company has built its technology story around a distinctive pulse architecture, most notably its 650-microsecond 1064nm Nd laser technology, with devices designed to support clinical versatility across varied skin types and treatment settings.
Aerolase is exclusively distributed by Beauty Technology in Australia, providing local clinical education, training and ongoing support.
Designed for modern clinical workflows
Over the past three decades, laser and energy-based devices have become an increasingly important part of dermatological and aesthetic practice. For clinics, the value of these technologies is no longer measured by single treatment categories alone, but by how well they can be integrated into practitioner-led protocols, support patient selection and adapt to the needs of a diverse patient base.
Aerolase says its devices are now used in more than 70 countries globally, reflecting both the brand’s longevity and the continued demand for laser platforms that can be applied across a broad range of clinical and aesthetic indications.
In addition to its 650-microsecond 1064nm Nd technology, the company’s broader portfolio also includes 300-microsecond pulse architecture, with both technologies forming part of Aerolase’s positioning around precision, versatility and efficient clinical integration.
For practitioners, the technology story is closely linked to the realities of daily practice: patient diversity, skin-type considerations, workflow, comfort, downtime expectations and the need for protocols that can be tailored to individual patients.
Sean Johnson, VP of Marketing at Aerolase, said the company’s anniversary reflects a long process of engineering refinement and practitioner feedback:
‘Thirty years of focused engineering means practitioners today are working with technology that has been refined through ongoing clinical feedback and real-world use. For Aerolase, each development in our 650- and 300-microsecond pulse architecture has been shaped by what matters in the treatment room: supporting practitioners treating a broad range of Fitzpatrick skin types, enabling clinical versatility across dermatological and aesthetic applications, and helping practices deliver efficient protocols with minimal disruption to patients’ routines, depending on the treatment performed and individual patient factors.
‘In 2026, that accumulated experience remains central to how we support healthcare practitioners in daily practice.’
The milestone also comes at a time when clinics are placing greater emphasis on technologies that can support personalised treatment planning. In aesthetic medicine, device selection is increasingly viewed through a broader clinical lens, including patient history, skin type, indication, treatment goals and how energy-based treatments may complement other modalities within a long-term care plan.
For Aerolase, its 30-year anniversary is less about looking back at a single product moment and more about the evolution of a technology platform that has remained in motion alongside the needs of modern clinical practice.
Always read the label and follow the directions for use. Aerolase is distributed by Beauty Technology. To arrange a clincial demonstration, contact info@beautytechnology.com.au or visit beautytechnology.com.au.
